NCT03875235 2026-03-19
TOPAZ-1
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
48 trialsNCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03785873 2026-02-13
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT03797326 2025-11-17
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04466891 2025-09-15
HERIZON-BTC-01
Jazz Pharmaceuticals
Phase 2 Completed
NCT05429203 2025-09-15
Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope
Stanford University
Phase NA Completed
NCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04057365 2025-08-13
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Massachusetts General Hospital
Phase 2 Terminated
NCT02711553 2025-08-03
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Active not recruiting
NCT06024174 2025-07-22
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03639935 2025-06-03
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03447470 2025-01-29
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
Redx Pharma Ltd
Phase 1 Completed
NCT04338685 2024-12-09
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Hoffmann-La Roche
Phase 1 Completed
NCT04683939 2024-10-02
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
Phase 1/2 Terminated
NCT02443324 2024-07-31
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT04677504 2024-07-03
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT03230318 2023-12-19
FIDES-01
Basilea Pharmaceutica
Phase 2 Completed
NCT03531320 2023-11-24
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
InnoPharmax Inc.
Phase 1/2 Completed
NCT04066491 2023-11-14
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono
Phase 2/3 Terminated
NCT03833661 2023-10-25
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
EMD Serono
Phase 2 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT04566133 2023-08-21
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01752920 2023-06-05
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Basilea Pharmaceutica
Phase 1/2 Completed
NCT03790111 2023-04-19
TELE-ABC
TerSera Therapeutics LLC
Phase 2 Terminated
NCT02821754 2023-03-28
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03101566 2022-10-28
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02489422 2022-10-14
PRO-YOU
Wake Forest University Health Sciences
Phase NA Completed
NCT02703714 2022-01-25
Pembrolizumab and GM-CSF in Biliary Cancer
University of California, San Francisco
Phase 2 Completed
NCT03111732 2021-12-03
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03093870 2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3 Completed
NCT02579616 2020-12-23
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
Eisai Inc.
Phase 2 Completed
NCT01099631 2020-07-20
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00948935 2020-03-11
Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01853618 2019-12-10
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01679405 2019-09-06
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
Johannes Gutenberg University Mainz
Phase 1 Terminated
NCT02053376 2019-01-30
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
University of Pittsburgh
Phase 2 Completed
NCT00955721 2018-01-03
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
University of Miami
Phase 1/2 Terminated
NCT01943864 2017-05-31
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
GlaxoSmithKline
Phase 2 Completed
NCT01661114 2016-10-19
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00753675 2016-10-10
VANGOGH
Sanofi
Phase 2 Completed
NCT00868998 2016-05-23
GTX Regimen for Biliary Cancers
Columbia University
Phase 2 Terminated
NCT01949870 2016-05-13
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
AstraZeneca
Phase 1 Terminated
NCT00881504 2014-10-20
A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
Georgetown University
Phase 2 Terminated
NCT00338988 2012-08-01
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00196105 2011-10-03
Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)
Cook Group Incorporated
Phase NA Completed
NCT00380588 2009-11-20
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Completed